A Phase 1, Randomized Ascending Single‐Dose Study of Antagonist Anti‐Human CD40 ASKP1240 in Healthy Subjects

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 13, Iss. 4, 2013-04 ,pp. : 1040-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pegfilgrastim Administered on the Same Day with Dose-Dense Adjuvant Chemotherapy for Breast Cancer Is Associated with a Higher Incidence of Febrile Neutropenia as Compared to Conventional Growth Factor Support: Matched Case-Control Study of the Hellenic Cooperative Oncology Group

By  

Oncology, Vol. 77, Iss. 2, 2009-07 ,pp. : 107-112

Karger

Access to resources Recommend Favorite

Phase 1, open‐label, dose escalation, safety, and pharmacokinetics study of ME‐344 as a single agent in patients with refractory solid tumors

By  

CANCER, Vol. 121, Iss. 7, 2015-04 ,pp. : 1056-1063

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 12, 2015-12 ,pp. : 1011-1019

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inclusion of Placebos and Blinding for Ascending Dose First‐in‐Human Studies and Other Underpowered Phase 1 Studies has not been Justified and on Balance is Not Useful

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 1, 2015-07 ,pp. : 44-51

John Wiley & Sons Inc

Access to resources Recommend Favorite